Director at Scientific Industries (SCND) granted 44,000 stock options

Rhea-AI Filing Summary

Scientific Industries Inc. director Michael Blechman received grants of stock options covering a total of 44,000 shares of common stock on February 17, 2026. The awards consist of 24,000 and 20,000 option shares, each with an exercise price of 0.6000 and expiration on February 17, 2036.

The options were granted in lieu of cash director fees and vest over one year at 1/12 per month, providing compensation rather than reflecting open-market buying. Following these grants, Blechman directly holds 116,186 stock options linked to the company’s common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BLECHMAN MICHAEL

(Last) (First) (Middle)

3928 LIVE OAK BLVD

(Street)

DELRAY BEACH FL 33446

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SCIENTIFIC INDUSTRIES INC [ SCND ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$0.6	02/17/2026	02/17/2026	A		24,000		02/17/2027(1)	02/17/2036	Common Stock	24,000	$0	96,186	D
Stock Option	$0.6	02/17/2026	02/17/2026	A		20,000		02/17/2027	02/17/2036	Common Stock	20,000	$0	116,186	D

Explanation of Responses:

1. Options granted to Registrant in lieu of cash fees. Vesting 1 year - 1/12th per month.

	Michael Blechman	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Scientific Industries (SCND) director Michael Blechman report on this Form 4?

Director Michael Blechman reported receiving two stock option grants totaling 44,000 underlying common shares. These derivative awards are compensation-related, not open-market purchases, and increase his directly held stock options to 116,186 tied to Scientific Industries’ common stock.

What are the key terms of Michael Blechman’s new stock option awards at SCND?

Blechman received options for 24,000 and 20,000 underlying common shares at a conversion price of 0.6000. Both grants were issued on February 17, 2026, and are scheduled to expire on February 17, 2036, giving him a long-dated equity incentive position.

How do these option grants for SCND’s director vest over time?

The options were granted in lieu of cash director fees and vest over one year. Vesting occurs at a rate of one-twelfth per month, gradually delivering full vesting over twelve months from the grant date, aligning compensation with continued Board service.

Did Michael Blechman buy or sell any Scientific Industries (SCND) shares in the market?

The Form 4 shows no open-market buys or sells. Instead, it reports compensation-related stock option grants, coded as awards (transaction code A), which give Blechman rights to acquire common shares in the future at a fixed exercise price.

What is Michael Blechman’s option position in Scientific Industries after these grants?

After the reported grants, Blechman directly holds 116,186 stock options linked to Scientific Industries common stock. This total reflects the addition of the two new awards, expanding his derivative-based equity exposure to the company as a board member.